Stallergenes Sa (STLEF) 59.9900 $STLEF
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g4fb7t/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - AllerR - BM-34 - Drug for Ragweed Pollen Allergy - Multi-LAMP-Vax - PL-101 - Pollinex Ragweed - ragweed hypoallergenic vaccin - Ragweed-SPIRE For more information visit http://www.researchandmarkets.com/research/g4...ed_allergy
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jjl3r/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Bial - Portela & Ca, S.A. - BioTech Tools s.a. - Circassia Pharmaceuticals plc - Greer Laboratories, Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Laboratorios LETI S.L. - Stallergenes S.A. Drug Profiles - Acaroid - AL-0704rP - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergovac - AllerT - Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Avanz Phleum Pratense - Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Depigoid Birch - Dermatophagoides Pteronyssinus Allergen Extract - gpASIT TM - Grass Pollen Allergoid - Grass-SPIRE - House Dust Mite-SPIRE - JRC2-LAMP-vax - MK-8237 - Olea Europaea Pollen Extract - Pollinex Quattro Grass - Ragweed Pollen Extract - rBet v1 - rBet v1-FV - rPhleum For more information visit http://www.researchandmarkets.com/research/8jjl3r/allergic
Global Allergic Asthma Pipeline Review 2015
M2 - Wed May 27, 11:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7j82mp/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Asmacure Ltee - BioTech Tools s.a. - Fountain Biopharma Inc. - Genentech, Inc. - Infinity Pharmaceuticals, Inc. - Kineta, Inc. - Marinomed Biotechnologie GmbH - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Panacea Biotec Limited - Peptinnovate Limited - Pharmaxis Limited - Portola Pharmaceuticals, Inc. - Protectimmun GmbH - Pulmatrix, Inc. - Stallergenes S.A. - sterna biologicals Gmbh & Co KG - Verona Pharma Plc For more information visit http://www.researchandmarkets.com/research/7j...gic_asthma
PTLA: 46.44 (+1.05), INFI: 10.19 (+0.23), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09)
Global House Dust Mite Allergy Pipeline Report 2015 - 7 Companies & 9 Drug Profiles
M2 - Wed May 20, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s4jvmr/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - DBV Technologies S.A. - HAL Allergy BV - Stallergenes S.A. Drug Profiles - AllerDM - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - allergenic pollen extract of timothy - BM-35 - House Dust Mite-SPIRE - MK-8237 - PL-103 - S-524101 - Viaskin House Dust Mite For more information visit http://www.researchandmarkets.com/research/s4..._dust_mite
Stallergenes Continues To Play Games With Minority Shareholders
Early Retiree - at Seeking Alpha - Fri May 15, 10:04AM CDT
Stallergenes-Greer Takeover Getting Messy
Early Retiree - at Seeking Alpha - Thu Apr 09, 5:30PM CDT
Is The Stallergenes-Greer Merger Good For Minority Shareholders?
Early Retiree - at Seeking Alpha - Fri Mar 06, 10:40AM CST
Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Mon Mar 02, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4g5s4/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering. Birch Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - Drug for Birch Pollen Allergy - PL-102 - rBet v1 - rBet v1-FV For more information visit http://www.researchandmarkets.com/research/d4...rch_pollen
What To Buy In Europe
Early Retiree - at Seeking Alpha - Sun Feb 22, 4:01AM CST
SNY: 51.49 (+2.71)
Global Cedar Pollen Allergy Pipeline Therapeutics Review, H2 2014 - 8 Companies & 11 Drug Profiles
M2 - Wed Jan 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrv8ls/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. Drug Profiles - AllerJ - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - Japanese Cedar Hypoallergenic Vaccine - JCC-LAMP-Vax - JRC-LAMP-Vax - MC-LAMP-Vax - Pollinex Quattro Japanese Cedar - RGI-1001 - TO-206 - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/hr...dar_pollen
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 46.44 (+1.05), AZN: 66.45 (+1.90), INFI: 10.19 (+0.23), NVS: 103.22 (+3.20)
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 57.95 (+0.57)
STALLERGENES And ActoGenix To Develop An Innovative New Class Of Oral Allergy Treatments
PR Newswire - Thu Nov 20, 11:00AM CST
STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today that it has exercised the option to pursue the exclusive development of an innovative new class of oral allergy treatments in partnership with ActoGeniX NV, creator of ActoBiotics(TM), in accordance with the contract signed in December 2013.
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Update: Stallergenes Stable As Usual, But Growth Lies Ahead
Early Retiree - at Seeking Alpha - Thu Oct 23, 1:42PM CDT
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g4fb7t/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - AllerR - BM-34 - Drug for Ragweed Pollen Allergy - Multi-LAMP-Vax - PL-101 - Pollinex Ragweed - ragweed hypoallergenic vaccin - Ragweed-SPIRE For more information visit http://www.researchandmarkets.com/research/g4...ed_allergy
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jjl3r/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Bial - Portela & Ca, S.A. - BioTech Tools s.a. - Circassia Pharmaceuticals plc - Greer Laboratories, Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Laboratorios LETI S.L. - Stallergenes S.A. Drug Profiles - Acaroid - AL-0704rP - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergovac - AllerT - Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Avanz Phleum Pratense - Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Depigoid Birch - Dermatophagoides Pteronyssinus Allergen Extract - gpASIT TM - Grass Pollen Allergoid - Grass-SPIRE - House Dust Mite-SPIRE - JRC2-LAMP-vax - MK-8237 - Olea Europaea Pollen Extract - Pollinex Quattro Grass - Ragweed Pollen Extract - rBet v1 - rBet v1-FV - rPhleum For more information visit http://www.researchandmarkets.com/research/8jjl3r/allergic
Global Allergic Asthma Pipeline Review 2015
M2 - Wed May 27, 11:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7j82mp/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Array BioPharma Inc. - Aslan Pharmaceuticals Pte. Ltd. - Asmacure Ltee - BioTech Tools s.a. - Fountain Biopharma Inc. - Genentech, Inc. - Infinity Pharmaceuticals, Inc. - Kineta, Inc. - Marinomed Biotechnologie GmbH - NeoPharm Co., Ltd. - Novartis AG - Nuvo Research Inc. - Panacea Biotec Limited - Peptinnovate Limited - Pharmaxis Limited - Portola Pharmaceuticals, Inc. - Protectimmun GmbH - Pulmatrix, Inc. - Stallergenes S.A. - sterna biologicals Gmbh & Co KG - Verona Pharma Plc For more information visit http://www.researchandmarkets.com/research/7j...gic_asthma
PTLA: 46.44 (+1.05), INFI: 10.19 (+0.23), NVS: 103.22 (+3.20), ARRY: 6.84 (+0.09)
Global House Dust Mite Allergy Pipeline Report 2015 - 7 Companies & 9 Drug Profiles
M2 - Wed May 20, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s4jvmr/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - DBV Technologies S.A. - HAL Allergy BV - Stallergenes S.A. Drug Profiles - AllerDM - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - allergenic pollen extract of timothy - BM-35 - House Dust Mite-SPIRE - MK-8237 - PL-103 - S-524101 - Viaskin House Dust Mite For more information visit http://www.researchandmarkets.com/research/s4..._dust_mite
Stallergenes Continues To Play Games With Minority Shareholders
Early Retiree - at Seeking Alpha - Fri May 15, 10:04AM CDT
Stallergenes-Greer Takeover Getting Messy
Early Retiree - at Seeking Alpha - Thu Apr 09, 5:30PM CDT
Is The Stallergenes-Greer Merger Good For Minority Shareholders?
Early Retiree - at Seeking Alpha - Fri Mar 06, 10:40AM CST
Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Mon Mar 02, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4g5s4/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering. Birch Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - Drug for Birch Pollen Allergy - PL-102 - rBet v1 - rBet v1-FV For more information visit http://www.researchandmarkets.com/research/d4...rch_pollen
What To Buy In Europe
Early Retiree - at Seeking Alpha - Sun Feb 22, 4:01AM CST
SNY: 51.49 (+2.71)
Global Cedar Pollen Allergy Pipeline Therapeutics Review, H2 2014 - 8 Companies & 11 Drug Profiles
M2 - Wed Jan 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrv8ls/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. Drug Profiles - AllerJ - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - Japanese Cedar Hypoallergenic Vaccine - JCC-LAMP-Vax - JRC-LAMP-Vax - MC-LAMP-Vax - Pollinex Quattro Japanese Cedar - RGI-1001 - TO-206 - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/hr...dar_pollen
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 46.44 (+1.05), AZN: 66.45 (+1.90), INFI: 10.19 (+0.23), NVS: 103.22 (+3.20)
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 57.95 (+0.57)
STALLERGENES And ActoGenix To Develop An Innovative New Class Of Oral Allergy Treatments
PR Newswire - Thu Nov 20, 11:00AM CST
STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today that it has exercised the option to pursue the exclusive development of an innovative new class of oral allergy treatments in partnership with ActoGeniX NV, creator of ActoBiotics(TM), in accordance with the contract signed in December 2013.
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Update: Stallergenes Stable As Usual, But Growth Lies Ahead
Early Retiree - at Seeking Alpha - Thu Oct 23, 1:42PM CDT
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
